RESEARCHERS from the Lifespan Cancer Institute announced results of a cancer vaccine clinical trial that showed the vaccine can improve survival rate of patients with brain tumors. / COURTESY RHODE ISLAND HOSPITAL
PROVIDENCE – Lifespan Cancer Institute researchers Friday announced they have made "a breakthrough" in treating patients with an aggressive brain cancer. Researchers said the Phase III trial of the DCVax-L vaccine showed improved the survival rates in patients with newly diagnosed and returning glioblastoma, the most common and most lethal form of brain cancer. Dr.…
Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.
